CCI approves Serum Institute Life Sciences-Biocon Biologics deal
OFB Tech's majority stake buy in SMW Ispat also cleared19-05-2022
19-05-2022
BIOCON LTD. - 532523 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended March 31, 2022, drawn in accordance with applicable accounting standard. The above information will also be available on the website of the Company at www.biocon.com.12-05-2022
BIOCON LTD. - 532523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report of the Company for the financial year 2021-22 dated April 28, 2022, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V Sreedharan and Associates, Practicing Company Secretaries.11-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meet10-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meeting10-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is further to our earlier letter dated April 29, 2022 regarding presentation and video recording of Q4 and full year FY22 Earnings Call held on April 29, 2022, please find enclosed herewith the transcript of the Earnings Call. The same is also available on the website of the Company at https://www.biocon.com/investor-relations/financial-information/earning-call-transcripts/.06-05-2022
Ireland regulator reports manufacturing deficiency at Biocon's plant
Biocon Biologics is a subsidiary of Biocon Ltd04-05-2022
BIOCON LTD. - 532523 - Notification To Stock Exchanges
HPRA Completes Audit of Biocon Biologics New mAbs Drug Substance Facility in Bengaluru 'This is to inform you that the Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, India, between March 28 and April 1, 2022. The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency. This facility will help us address the additional requirements of our products in EU market.' - Biocon Biologics Spokesperson03-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement- Financial Results Quarter and Financial Year ended March 31, 202201-05-2022
Buy Biocon: target of Rs 420: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 420 in its research report dated April 29, 2022.30-04-2022